Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-05-27
DOI
10.1016/s2213-2600(22)00131-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
- (2021) Mark W. Tenforde et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
- (2021) Alejandro Jara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
- (2021) Moriah Bergwerk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Scent of a vaccine
- (2021) Frances E. Lund et al. SCIENCE
- COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact
- (2021) David A. Swan et al. Scientific Reports
- BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
- (2021) Patrick Tang et al. NATURE MEDICINE
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020
- (2020) Marie E. Killerby et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Characteristics of Persons Who Died with COVID-19 — United States, February 12–May 18, 2020
- (2020) Jonathan M. Wortham et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
- (2020) Takuya Sekine et al. CELL
- COVID-19 Makes B Cells Forget, but T Cells Remember
- (2020) Pablo F. Cañete et al. CELL
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines
- (2019) Pui Wang et al. mBio
- Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung
- (2016) K M Morabito et al. Mucosal Immunology
- Mucosal immunity and nasal influenza vaccination
- (2012) Markus A Rose et al. Expert Review of Vaccines
- The Magnitude of Local Immunity in the Lungs of Mice Induced by Live Attenuated Influenza Vaccines Is Determined by Local Viral Replication and Induction of Cytokines
- (2010) Y.-F. Lau et al. JOURNAL OF VIROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now